

CLAIMS

What is claimed is:

1. A process for the preparation of sidechain-bearing cephalotaxane of the following formula and/or a salt thereof




where

Ω ("omega") is a representative radical of the chain terminal moiety and -CO- is the carbonyl of the ester group bonded to cephalotaxane;

the $\Omega\text{-CO-}$ radical is corresponding:

- either to the following substituted heterocycloalkane formula:



where n is included between 0 and 8;

Z is oxygen, nitrogen or sulfur heteroatom;

R^5 , R^6 and R^8 are independently hydrogen;


hydrocarbon radical, saturated, unsaturated or aromatic, linear or ramified and/or cyclic, especially alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, of said radical including or not heteroatom(s); R^6 and R^8 may be included in a cycle ;

oxygen ether bearing one of the former radicals;

- or to the following linear alkene formula:

Sub 7
a'


09270006-031699



where m is included between 1 and 8;

R^5 , R^6 and R^8 are as defined above;

- or to the following formula:



where n, R^5 , R^6 and R^8 are as defined above;

Z and Q^2 are independently oxygen, nitrogen or sulfur heteroatom;

Q^1 is carbon, silicon or phosphorus atom;

R^9 and R^{10} are independently hydrogen, alkoxy, hydrocarbon radical, including or not heteroatom(s), saturated, unsaturated or aromatic, linear or ramified and/or cyclic, especially alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl;

R^9 and/or R^{10} having the ability to be null or taken together to make an heteroatom and/or make a multiple bond with Q^1 , R^9 and R^{11} having the ability to be null to make a multiple bond between the two atoms of carbon bearing them; and


R^{11} is hydrogen, arylcarbonyl, alkoxy carbonyl, aryloxy carbonyl or alkylcarbonyl;

where

Sub a' >
cont.

09270006-031699

-O-CTX is cephalotaxine moiety of the following formula a salt thereof:




where p is equal to 1 or 2;

the two types of radicals -Ω and -CTX above-mentioned being bonded with an ester bond -CO-O-


the said process bringing together:

- either carboxylic acid with general formula Ω-CO-OH or a salt thereof;
- or an activated form of an acid with general formula Ω-CO-A or a salt thereof, with Ω-CO of the following formula:




where n, Z, R⁵, R⁶ and R⁸ are as defined above;

where Ω-CO of the following formula:



m is included between 1 and 8, Z, R⁵, R⁶ and R⁸ are as defined above;


where Ω-CO of the following formula:



where n , Z , Q^1 , Q^2 , R^5 , R^6 , R^8 , R^9 , R^{10} and R^{11} are as defined above

A represents:

- either cyclic anhydride of the following formula:



5


where n , R^6 and R^8 are as defined above;

this reaction has been completed by methylation of the primary carboxyl thus formed, with:

- either a hydroxyl group bearing cephalotaxane or a salt thereof of the formula H-O-CTX, where CTX are as defined above;
 - or a metallic alcoxide of the formula M-O-CTX, where CTX are as defined above and M is a metal;
 - or an activated form of its hydroxyl group of the formula Y-O-CTX, where -O-CTX is as defined above and Y is, either a leaving group to allow a negative charge on oxygen atom by cleavage between Y- and -O-CTX, or to allow a carbocation by cleavage between Y-O- and -CTX;
- with the possible presence of one or several reaction additives to form said sidechain-bearing cephalotaxane and/or a salt thereof.


20 2. The process according to claim 1, wherein Z is an oxygen atom and the cephalotaxane H-O-CTX is a cephalotaxine of the following formula, or a salt

2. The process according to claim 1, wherein Z is an oxygen atom and the cephalotaxane H-O-CTX is a cephalotaxine of the following formula, or a salt thereof:



where R^1 , R^2 , R^3 and R^4 are independently hydrogen, hydroxyl group or alkoxide.

3. The process according to claim 2, wherein said cephalotaxane H-O-CTX is cephalotaxine, or a salt thereof, where R^1 is hydroxyl, R^2 is methoxyl, R^3 and R^4 are hydrogen.



4. The process according to ^{claim 1} ~~anyone of claims 1 to 3~~, wherein R^5 is hydrogen.

5. The process according to ^{claim 1} ~~anyone of claims 1 to 3~~, wherein R^5 is $-\text{CH}_2\text{CO-O-Me}$.

6. The process according to ^{claim 1} ~~anyone of claims 1 to 5~~, wherein $n = 1$ to 4, R^6 and R^8 are methyl.

09270006-031699

a 7. The process according to ^{claim 1} ~~anyone of claims 1 to 5~~, wherein $n = 1$ or 2 , R^6 is phenyl and R^8 is hydrogen.


5 8. The process according to ^{claim 1} ~~anyone of claims 1 to 5~~, wherein, R^5 is $-\text{CH}_2\text{-CO-O-Me}$, said cephalotaxane is the former of claim 3, $n = 0$, Z is a nitrogen atom and R^8 is hydrogen.

a
a 10 9. The process according to ^{claim 1} ~~anyone of claims 1 to 8~~, wherein A is $\Omega\text{-CO-O-}$ radical where Ω is as defined according to ^{claim 1} ~~claim 1~~.


a
a 10. The process according to ^{claim 1} ~~anyone of claims 1 to 8~~, wherein A is halide.

15 11. The process according to ^{claim 1} ~~anyone of claims 1 to 8~~, wherein A is a radical of compound $\Omega\text{-CO-A}$ having the ability to generate cleavage of the bond between carbonyl group and substituent A of $\Omega\text{-CO-A}$ to provide $\Omega\text{-CO}^+$ and A^\cdot

a 20 12. The process according to ^{claim 1} ~~anyone of claims 1 to 8~~, wherein A is a radical selected from substituents:
méthoxyformyloxy of formula MeOCOO- ,
trifluoroacétyloxy of formula $\text{CF}_3\text{COO-}$,
alkylsulfonyloxy of formula $\text{RSO}_3\text{-}$,
phosphoxy of formula $(\text{RO})_2\text{PO-}$,
halophosphoxy of formula $\text{ROP}(\text{Cl})\text{O-}$,
25 trialkylsilyloxy of formula $\text{R}_3\text{SiO-}$,
diméthyl-formamidineum chloride of formula:



or acyloxy-pyridinium bromide of formula:




formulas wherein R is alkyl.

5 13. The process according to ^{claim 1} ~~anyone of claims 1 to 8~~, wherein A is 2,4,6-trichlorobenzoyloxy radical

14. The process according to claim 13, wherein reagent of formula Ω -CO-A, A is 2,4,6-trichlorobenzoyloxy radical, is obtained by contacting an acid Ω -CO-OH, as defined according to claim 1, with 2,4,6-trichlorobenzoyl chloride in
10 presence of one or more O-acylation additives.

15. The process according to ^{claim 1} ~~anyone of claims 1 to 8~~, wherein radical A is corresponding to the following formula:



15 16. The process according to claim 15, wherein reagent of formula Ω -CO-A is obtained by contacting an acid Ω -CO-OH, ~~as defined according to claim 1~~, with carbonyl-diimidazole in presence of a strong base.

20 17. The process according to claim 16, wherein strong base is an alkoxide.

18. The process according to ^{claim 1} ~~previous claims~~, wherein the coupling additive is a substituted carbodiimide and/or a basic additive ~~such as tertiary amine for example.~~

19. The process according to claim 18, wherein the substituted carbodiimide is selected from cyclohexylcarbodiimide (DCC), 1,3-diisopropylcarbodiimide (DIC) and chlorhydrate of 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide.

20. The process according to ^{claim 1} ~~anyone of previous claims~~, wherein cephalotaxine alcoxide ^{corresponds} ~~is corresponding~~ to the following formula:



~~where M and CTX are as defined according to claim 1,~~

is obtained by contacting a cephalotaxine of the following formula:




~~where CTX is as defined according to claim 1~~


with metal ~~himself~~, an amidure, a metallic hydride or an alkyl-metal.

21. The process according to anyone of claims 1 to 20, wherein M is alkaline metal such as lithium, potassium or sodium.


22. The lithium alcoxide of cephalotaxine ~~is corresponding~~ to the following formula:



23. The sodium alcoxide of cephalotaxine ~~is corresponding~~ to the following formula:



24. A sidechain-bearing cephalotaxane corresponding to the following formula and/or a salt thereof:



where

n is included between 0 and 8;

Z is oxygen, nitrogen or sulfur heteroatom;

R^5 , R^6 and R^8 are independently

hydrogen;

hydrocarbon radical, saturated, unsaturated or aromatic, linear or ramified and/or cyclic, especially alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, of said radical including or not heteroatom(s);

oxygen ether bearing one of the former radicals;

CTX is as defined according to anyone of claims 1 to 3;

except for compounds where Z is oxygen atom and,

1°) $n = 2$ or 3 , and simultaneously $R^6 = R^8 = \text{methyl}$ and $R^5 = \text{OMe}$ or hydroxyl,

1°) $n = 2$ and simultaneously $R^6 = R^8 = \text{methyl}$ and $R^5 = \text{OMe}$ or hydroxyl;

3°) $n = 3$ and simultaneously R^6 is hydroxyl, when R^8 is methyl and R^5 is $-\text{CH}_2\text{CO}_2\text{CH}_3$ radical.

09270006-031699

5

10


15

20

Sub
Q3

Sub
a3 cent?

25. A sidechain-bearing cephalotaxane corresponding to the following formula and/or a salt thereof:



5

where

m , R^5 , R^6 and R^8 are as defined according to claim 1, and CTX is as defined according to anyone of claims 1 to 3,


10

Except compound where $m = 2$, $R^5 = \text{CH}_2\text{CO}_2\text{CH}_3$, $R^6 = R^8 = \text{methyl}$ and CTX is as defined according to claim 3.

15

26. The cephalotaxane according to claim 25, wherein R^5 is $-\text{CH}_2\text{-CO-O-CH}_3$ radical.

27. A sidechain-bearing cephalotaxane corresponding to the following formula and/or a salt thereof:



20

where n , Z , Q^1 , Q^2 , R^5 , R^6 , R^8 , R^9 , R^{10} and R^{11} are as defined according to claim 1, and CTX is ^{claim 1} as defined according to ~~anyone of~~ ~~claims 1 to 3,~~

28. The cephalotaxane according to claim 27, wherein Q^2 is oxygen atom.

09270006-031699


Q
Q

29. The cephalotaxane according to claim 28, wherein Z is nitrogen atom.

30. The cephalotaxane according to claim 29, wherein $n = 0$.


5

31. The sidechain-bearing cephalotaxane corresponding to the following formula:




32. The sidechain-bearing cephalotaxane corresponding to the following formula:

10




33. The sidechain-bearing cephalotaxane corresponding to the following formula:




claim 1
34. The process according to ~~any one of claims 1 to 24~~, wherein

- 5 - when the cyclic side-chain of sidechain-bearing cephalotaxane, and/or a salt thereof, of the following formula:



where n, R⁵, R⁶, R⁸, CTX and Z are as defined according to claim 1;

- 10 the said chain is open with an agent and/or a protonic or not protonic electrophilic radical E in aqueous or not aqueous medium, to provide an intermediate compound of the following formula:




where n, CTX, R⁵, R⁶ and R⁸ are as defined above, E is either
15 hydrogen or the provisionally or definitively fixed electrophilic radical;

the aforementioned intermediate compound may be attacked with an agent or a nucleophilic radical Z', deliberately added or possibly present in the medium, and

5


- when the cyclic side-chain of sidechain-bearing cephalotaxane, and/or a salt thereof, of the following formula:



- where n, R⁵, R⁶, R⁸, R⁹, R¹⁰ and R¹¹ are as defined according to claim 1, and Z' is an heteroatom;

the said chain is open by hydrolysis or carefully solvolysis with possibly presence of activation and/or opening additive;

- to provide an open sidechain-bearing cephalotaxane of the following formula:



where n, CTX, R⁵, R⁶ and R⁸ are as defined according to claim 1;

Z' is:


- either an halogen or an heteroatom bearing a hydrogen or a radical R¹¹ such as defined accordint to claim 1;

20

- or an hydrogen, hydrocarbon radical, the said radical bearing ^{optionally} or not ^{unsaturated} heteroatom(s), saturated, ^{branched} or aromatic, linear or ^{branched} and/or cyclic, ~~especially alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, or~~

~~heterocycloalkyl:~~


35. The process according to the claim 34 wherein the cyclic side-chain of sidechain-bearing cephalotaxane, and/or a salt thereof, of the following formula:



5

where n , R^8 , R^6 , R^5 , CTX and Z are defined according to the claim 1, the said chain is open by treatment with a solution of hydrobromic acid in acetic acid, in an halogenated solvent, preferably dichloromethane, followed by *in situ* hydrolysis to provide, without isolation of the intermediate, a sidechain-bearing cephalotaxane of the following formula:

10



~~where n , CTX , R^5 , R^6 et R^8 are defined according to claim 1.~~

15

36. The process according to ^{claim 1} ~~any one of claims 1 to 21 and claim 34~~, wherein acids are corresponding to the following formula :



~~where Ω radical is as defined according to claim 1,~~

the said formula equivalent to racemic mixture containing compounds of the formulas $(+)\text{-}\Omega\text{-CO-OH}$ and $(-)\text{-}\Omega\text{-CO-OH}$ ^{wherein} such as $(+)\text{-}\Omega\text{-CO-OH}$ represents its dextrogyre enantiomer and $(-)\text{-}\Omega\text{-CO-OH}$ represent its levogyre enantiomer.

20

were obtained

a) by contacting of said racemic mixture or one of its activated ^{the} ~~form~~ ^{forms} of the

09270006-031699

formula



which is as defined according to claim 1;

5 the said racemic mixture or said activated form generating respectively:

- either an anion corresponding to the formula $(\Omega\text{-CO-O})^-$;
- or a cation corresponding to the formula $(\Omega\text{-CO})^+$;

10 with a pure enantiomeric form of chiral entity, said "resolution agent" symbolized by Δ^* (delta stella), having the ability to form:

- either a stable combination, by covalent bonding;
- or an easily reversible labil combination, by hydrogen bonding or by hydrophobic interaction;
- 15 - or intermediate lability bonding by electrostatic interaction;

to provide a diastereomeric mixture of $\Omega\text{-CO-O-}\Delta^*$ and de $\Omega\text{-CO-}\Delta^*$;


20 b) then by physical separation of the mixture of two diastereomers or two complex compounds or more generally of two new entities physically and/or chemically different then obtained;

c) then by regeneration and finally separation of each one of enantiomers of the generic formula $\Omega^*\text{-CO-OH}$,

25 where Ω^* («oméga stella») represents the generic symbol of the same chiral radical in the either one or the other pure enantiomeric forms corresponding to the following formulas $(+)\text{-}\Omega\text{-CO-OH}$ and $(-)\text{-}\Omega\text{-CO-OH}$ which are as defined above.


30 37. The process according to claim 36, wherein $\Omega\text{-CO-}$ is a radical corresponding to the following formula:

09270006-031699




where n , Z , R^6 , R^8 , and R^5 are as defined according to claim 1.

38. The process according to claim 36, wherein Ω -CO- is a radical corresponding to the following formula:



where m , Z , R^6 , R^8 , and R^5 are as defined according to claim 1.

39. The process according to claim 36, wherein Ω -CO- is a radical corresponding to the following formula:



where n , R^5 , R^6 , R^8 , Z , Q^2 , Q^1 , R^9 , R^{10} and R^{11} are as defined according to claim 1.

40. The process according to ~~anyone of claims 36 to 39~~, wherein the stable combination is represented by an ester of the following formula $\Omega\text{-CO-O-}\Delta^*$ such as Ω and Δ^* are as defined according to claim 36, the said stable combination is obtained by contacting acid with a chiral alcohol corresponding to the formula $\text{HO-}\Delta^*$ such as Δ^* is as defined according to claim 36, according to the process of the claim 1.

41. The process according to ^{claim 36} ~~anyone of claims 36 to 39~~, wherein the stable combination is represented by an amide corresponding to the either one or the other formulas $\Omega\text{-CO-NH-}\Delta^*$ or $\Omega\text{-CO-N-}\Delta^*$ such as Ω and Δ^* are as defined according to claim 36, the said stable combination is obtained by contacting acid with primary or secondary chiral amine corresponding to formulas $\text{H}_2\text{N-}\Delta^*$ or $\text{NN=}\Delta^*$ such as Δ^* is as defined according to claim 36, according to the process of the claim 1.

42. The process according to ^{claim 36} ~~anyone of claims 36 to 39~~, wherein the stable combination is represented by a thioester of the following formula $\Omega\text{-CO-S-}\Delta^*$ such as Ω and Δ^* are as defined according to claim 36, the said stable combination is obtained by contacting acid with a chiral thiol corresponding to the formula $\text{HS-}\Delta^*$ such as Δ^* is as defined according to claim 36, according to the process of the claim 1.

43. The process according to ^{claim 36} ~~anyone of claims 36 to 39~~, wherein the ionic combination is represented by a salt just prepared by contacting of acid with a chiral amine corresponding to ^{one of the Ω or an} ~~the either one or the other of the three following~~ formulas:




where Ω and Δ^* are as defined according to claim 36.

44. The process according to ^{claim 36} ~~anyone of claims 36 to 39~~, wherein the bringing


into play of a ^{labile} ~~labile~~ bonding based combination is achieved in the form of chromatography with the help of a chiral stationary phase.

45. The process according to ^{claim 36} ~~any one of claims 36 to 39~~, wherein the bringing into play of an interatomic or intermolecular ^{labile} ~~labile~~ bonding based combination, within crystalline lattice, is achieved in the form of fractionated crystallization initiated by a chiral precursor.



46. The process according to claim 40, wherein chiral alcohol HO- Δ^* is (-)-quinine corresponding to the following formula:



47. The process according to claim 40, wherein chiral alcohol HO- Δ^* is (-)- or (+)-methyl mandelate corresponding to the following formulas:





48. The process according to claim 40, wherein chiral alcohol HO- Δ^* is (-)- or (+)-menthol corresponding to the following formulas:





49. The process according to claim 43, wherein chiral amine $H_2N-\Delta^*$ is (-)- or (+)-ephedrine corresponding to the following formulas:

5




50. The (-)-quinidyl (2'R)-(-)-anhydro-homoharringtonate and the (-)-quinidyl (2'S)-(-)-anhydro-homoharringtonate corresponding respectively to the two following formulas:




10


51. The (-)-menthyl (2'R)-(-)-anhydro-homoharringtonate and the (-)-menthyl (2'S)-(-)-anhydro-homoharringtonate corresponding respectively to the two following formulas:



52. The (-)-methylmandelyl (2'R)-(-)-anhydro-homoharringtonate and the (-)-methylmandelyl (2'S)-(-)-anhydro-homoharringtonate corresponding respectively to the two following formulas:




53. The (-)-ephedrinium (2'R)-(-)-anhydro-homoharringtonate and the (-)-ephedrinium (2'S)-(-)-anhydro-homoharringtonate corresponding respectively to the two following formulas:




54. The process according to ~~any one of claims 1 to 21 and 34 to 49~~, wherein the carboxylic acid is:

- 5 - either the tertiary heterocycloalkane carboxylic acid corresponding to the following formula:



where n , Z , R^5 , R^6 and R^8 are as defined according to claim 1.
the said acid is obtained by treatment in aprotic or protic solvent, eventually in the presence of cyclization additive and/or dehydrating agent, the said treatment eventually supported with physical carrying of the water formed;


- or open tertiary ethylenic acid corresponding to the following formula:



15 where m , Z , R^5 , R^6 and R^8 are as defined according to claim 1.

09270006-031699

- or open tertiary ethylenic acid corresponding to the following formula:



range from 1 to 8
 where m is included between 1 and 8, Z, R^5 , R^6 and R^8 are as defined according
 to claim 1, R^{12} , is not a CTX radical according to claim 1, represents R^5 and/or
 a protective group of acids and/or a chiral group;
 then R^{12} is removed later, either just by saponification, or by hydrogenolysis,
 or more generally by the method of the state of art to remove protective groups
 of acids.

55. The process according to claim 54, wherein in the absence of cyclization additive, the reaction of cyclization ~~just take place~~ ^{is conducted} by heating.

56. The process according to claim 54, wherein the cyclization additive is a protic acid or an aprotic acid, included in immobilized form.


57. The process according to claim 54, wherein the acid is sulfonic acid or formic acid.

claim 54
 58. The process according to ~~anyone of claims 54 to 57~~, wherein Z is an oxygen atom.

59. The tertiary heterocycloalkane carboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:

Sub 7
Q4

09270006-01699




where n is included between 1 and 8, Z, R⁵, R⁶ and R⁸ are as defined according to claim 1, and R⁵ is not hydrogen;

except for compounds where Z is oxygen atom and,

- 1°) n = 0 and R⁵ is not -CH₂CO₂H or -CH₂CO₂CH₃ radical;
- 2°) n = 0 and R⁵ is -CH₂CO₂H or -CH₂CO₂CH₃ radical, and R⁶ = R⁸ = methyl or -CH₂CO₂H or -CH₂CO₂CH₃ radical;
- 3°) n = 2 and simultaneously R⁶ = R⁸ = methyl, and R⁵ = OMe or hydroxyl ;
- 4°) n = 2 and simultaneously R⁶ = R⁸ = methyl, and R⁵ is -CH₂CO₂H or -CH₂CO₂CH₃ radical or methyl;
- 5°) n = 3 and simultaneously R⁶ is hydroxyl, and R⁸ is methyl, and R⁵ is -CH₂CO₂CH₃ radical;
- 6°) n = 3 and simultaneously R⁶ = R⁸ = methyl and R⁵ = OH or methyl or ethyl.

60. The tertiary oxacycloalcanecarboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:




where n is included between 0 and 8, R⁵, R⁶ and R⁸ are as defined according to claim 59, but are not hydrogen simultaneously.

Sub
Q4 cont.


09270006-031699

5




where n is included between 0 and 8, Z, R⁵, R⁶ and R⁸ are as defined according to claim 59, and R⁵ is not hydrogen, and R¹² is defined according to claim 54.

62. The tertiary oxacycloalcanecarboxylic hemiester, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:




15 where n is included between 0 and 8, R^6 and R^8 are as defined according to claim 59.

20




where n is included between 0 and 8, R^6 and R^8 are as defined according to claim 59, R^{12} is defined according to claim 54.

64. The tertiary oxacycloalcanecarboxylic hemiester or anhydro-homoharringtonic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:




65. The tertiary oxacycloalcanecarboxylic hemiester or anhydro-harringtonic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:



66. The tertiary oxacycloalcanecarboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition,


corresponding to the following formula:



where n is included between 0 and 8, R^5 is as defined according to claim 59.

5

67. The tertiary oxacycloalcanecarboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:




10

where n is included between 1 and 8.

68. The tertiary oxacycloalcanecarboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:

15




where n is included between 0 and 8.

69. The tertiary oxacycloalcanecarboxylic acid or oxanhydroneoharringtonic


09270006.031599

Sub
Q4 cont.

acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:




- 5 70. The tertiary oxacycloalkane carboxylic acid or oxanhydro-neohomoharringtonic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:



10

71. The tertiary oxacycloalkane carboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:




- 15 72. The tertiary alkene carboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:

Sub
at cont.

09270006-031699

Sub
24 cont.




where m is included between 1 and 8, R^6 and R^8 are as defined according to claim 1, but are not hydrogen simultaneously, and R^5 is not hydrogen or heteroatom.

5

73. The tertiary alkene carboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, ^{according to claim 54} corresponding to the following formula:

10




~~where m is included between 1 and 8, m' is included between 1 to 8, R^6 and R^8 are as defined according to claim 1 and and R^{12} is defined according to claim 54.~~

15


74. The tertiary alkene carboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:

Sub
25


Sub
ascent?

where m is included between 1 and 8, R^6 and R^8 are as defined according to claim 1 but are not hydrogen.

- 5 75. The tertiary alkene carboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:




- 10 76. The tertiary alkene carboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:



- 15 77. The tertiary alkene carboxylic acid, included its salts and each one of its pure enantiomeric forms or in racemic mixture or in variable composition, corresponding to the following formula:

09270006-031699

Sub
Q5cent.


where m is included between 1 to 8.

78. The compound according to claim 77, where $m = 1$.


79. The anhydrides of acid according to anyone of claims 58 to 70, of the general formula $\Omega\text{-CO-O-CO-}\Omega$ where Ω is as defined according to claim 1.

80. The mixed anhydrides of acid according to anyone of claims 58 to 70, of the general formula $\Omega\text{-CO-A}$ where A is as defined according to anyone of claims 12, 13 or 15.

81. The mixed anhydride corresponding to the following formula:




82. The acid chlorides according to ^{claim 58} anyone of claims 58 to 70, corresponding to the ~~general~~ formula $\Omega\text{-CO-X}$, where X is halogen.



83. The cyclic anhydrides corresponding to the following formula:

where n , R^6 and R^8 are as defined according to claim 1.

84. The cyclic anhydride corresponding to the following formula:



claim 1
85. The process according to ~~any one of claims 1 to 21 and 34 to 49~~ where the sidechain-bearing cephalotaxane was purified like a salt by chromatography using a reversed-phase like stationary phase, and a mobile phase without organic solvent like a solution adjusted to a pH 2 to 4.5 with a buffer prepared with an acid and an alkaline or ammonium salt and one or several additive like attenuator of silanol effect, the said cephalotaxane salt was generated from mineral acid under the form of chlorohydrate, sulfate, phosphate, nitrate, perchlorate, or from organic acid under the form of tartrate, malate, citrate or lactate.

Sub 7
a7


5

10

15


09270006-031699

claim 1
 86. The process according to anyone of claims 1 to 21 and 34 to 49 comprising a step of chromatographic purification of a natural or semi-synthetic or synthetic homoharringtonine as a pharmaceutical use corresponding to the following formula:




to remove the undesired related impurity named 2'-épi-homoharringtonine resulting:

a) either from a semi-synthetic process with introduction of a synthetic homoharringtonic acid of inadequate enantiomeric purity, the generated impurity showing the absolute configuration corresponding to the following formula:



b) or from the biosynthetic process in the plant, where a cephalotaxine with inadequate enantiomeric purity was introduced, or in the form of artefact by partial racemization of the cephalotaxine moiety, the generated impurity showing strictly identical chromatographic properties with a non-chiral system,

with an absolute configuration opposite to the one above (enantiomer) and corresponding to the following formula:



5 ^{using} ~~especially making use of~~ one of the following chromatographic systems:

A) Stationary phase:

alkyl- or phenyl- or alkylphenyl- or phenylalkyl-silane, preferably ~~n-octadecylsilane,~~

B) Mobile phase:

10 water-tetrahydrofurane, water-methanol, water-acetonitrile or buffer pH 2 to 6.5 in replacement of water, or all other mobile phase with equivalent selectivity,

87. The process of purification and chromatographic control according to the
 15 claim ~~86~~ of a natural or semi-synthetic or synthetic homoharringtonine, allowing to offset the double insufficiency of enantiomeric purity of the half-precursors, both on the sidechain precursor (said homoharringtonic acid) and cephalotaxine, the two said-precursors are each independently generated by total synthesis or semi-synthetic process or natural process within of the plant
 20 (biosynthesis), in fact the withdrawal of the non natural enantiomer of homoharrintonine showing an opposite absolute configuration, by using a chiral stationary phase with preparative scale.